These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17268348)

  • 1. [Evaluation criteria for bronchial carcinoma. Economic criteria in the management of lung cancer].
    Chouaid C
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S118-16S122. PubMed ID: 17268348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical-economic evaluation of lung cancers. Theoretical approaches and practical applications].
    Vergnenegre A; Chouaïd C; Lafuma A
    Rev Mal Respir; 1998 Sep; 15(4):469-78. PubMed ID: 9805757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analyses and lung cancer.
    Vergnenègre A; Molinier L; Chouaïd C
    Monaldi Arch Chest Dis; 2001 Aug; 56(4):336-43. PubMed ID: 11770217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stage IV NSCLC. Economic analysis in lung cancers].
    Vergnenègre A; Atsou K; Molinier L; Chouaïd C
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S127-37. PubMed ID: 18971837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical-economic evaluation of bronchial cancer].
    Vergnenegre A
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S38-9. PubMed ID: 10088236
    [No Abstract]   [Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
    Rosell R; Moran T; Fernanda Salazar M; Mendez P; De Aguirre I; Ramirez JL; Isla D; Cobo M; Camps C; Lopez-Vivanco G; Alberola V; Taron M
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S131-16S136. PubMed ID: 17268350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
    Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
    Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The place of targeted therapies in the management of non-small cell bronchial carcinoma. Biological mechanisms of bronchial carcinogenesis: towards a better understanding and the development of new therapies].
    Zalcman G; Richard N; Madelaine J; Bergot E
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S123-16S130. PubMed ID: 17268349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
    Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
    Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to take into account the cost effectiveness parameters in the management of bronchial carcinoma?].
    Vergnenègre A
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S17-10S20. PubMed ID: 17127955
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiology and costs of lung cancer in Germany].
    Weissflog D; Matthys H; Hasse J; Virchow JC
    Pneumologie; 2001 Jul; 55(7):333-8. PubMed ID: 11481580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation criteria for bronchial carcinoma. How to read a meta-analysis?].
    Paesmans M
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S105-16S111. PubMed ID: 17268346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The place of targeted therapies in the management of non-small cell bronchial carcinoma. Methodology of the development of targeted therapies in pulmonary oncology].
    Pérol M
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S148-16S157. PubMed ID: 17268352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic cost analysis in cancer management and its relevance today.
    Sharma K; Das S; Mukhopadhyay A; Rath GK; Mohanti BK
    Indian J Cancer; 2009; 46(3):184-9. PubMed ID: 19574668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer.
    Garattini L; Compadri PD; Koleva D; Pasina L; Nobili A
    J Med Econ; 2008; 11(1):177-97. PubMed ID: 19450119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.